Table 1 Demographic and clinical characteristics of patients with migraine and controls
From: Periaqueductal gray matter echogenicity as a marker of migraine chronification: a case control study
Controls (n = 50) | Migraine patients (n = 65) | CM (n = 39) | EM (n = 26) | p value (C vs M) | p value (CM vs EM) | |
|---|---|---|---|---|---|---|
Age (years) | 43.50 [28.00;65.00] | 45.00 [38.00;53.00] | 45.00 [38.00;53.00] | 45.00 [38.00;54.00] | 0.954 | 0.981 |
Sex, female (n,%) | 34 (68%) | 47 (72.3%) | 27 (69.23%) | 20 (76.92%) | 0.682 | 0.579 |
Disease duration (years) | - | 30.00 [20.00;40.00] | 29.00 [19.00;40.00] | 30.00 [22.00;40.00] | - | 0.384 |
Duration of CM (months) | - | - | 60.00 [40.00;120.00] | - | NA | |
Days of migraine per month | - | 14.00 [10.00;19.00] | 18.00 [14.00;27.00] | 9.00 [2.00;12.00] | - | < 0.001 |
Days of headache per month | - | 20.00 [12.00;30.00] | 28.00 [24.00;30.00] | 9.50 [3.00;12.00] | - | < 0.001 |
NSAIDs overuse (n,%) | - | - | 11 (28.21%) | 1 (3.85%) | - | 0.02 |
Triptans overuse (n,%) | - | - | 12 (30.77%) | 7 (26.92%) | - | 0.787 |
MIDAS, total score | - | 60.00 [20.00;96.00] | 84.00 [56.00;122.00] | 21.00 [3.50;36.50] | - | < 0.001 |
HIT-6 | 67.00 [62.00;70.00] | 68.00 [65.00;70.00] | 64.00 [55.50;67.00] | - | 0.004 | |
MSQV2.19 | 42.85 [30.00;65.58] | 34.29 [22.85;51.43] | 63.58 [46.43;88.58] | - | < 0001 | |
HADS Anxiety, score | - | 9.00 [6.00;14.00] | 11.00 [7.00;16.00] | 7.50 [4.00;10.00] | - | 0.002 |
HADS Depression, score | 6.00 [4.00;10.00] | 9.00 [5.00;12.00] | 4.00 [3.00;8.00] | - | 0.001 |